Yunnan Baiyao Group Co.Ltd(000538)
Minutes of investor research meeting
Time: April 1, 2022
Location: group headquarters office building
Holding method: teleconference
Investors: Guosheng Securities – Zhang Jinyang, Yang Chunyu
Participants: securities affairs representative – Zhao Yan, investor relations management – GUI Boxiang, project management – Li Mengjue
Meeting content
1. What is the strategic intention of the company?
A: the company has reached equity cooperation and strategic cooperation between the two sides by participating in the subscription of Shanghai Pharmaceuticals Holding Co.Ltd(601607) non-public offering of a shares. By virtue of Shanghai Pharmaceuticals Holding Co.Ltd(601607) high-quality platform and industrial resource coordination, the company has further amplified Yunnan Baiyao Group Co.Ltd(000538) existing resource advantages, grasped the important opportunities of industrial integration, expanded the scale of main business, the layout of existing industries, and improved the overall operation efficiency. Through regional complementarity, logistics, warehousing, purchase and price negotiation The integration and coordination of variety agency, brand promotion and new drug development is conducive to expanding the scale of main business, improving operation efficiency, and improving the core competitiveness and profitability of enterprises.
2. How will the company plan its securities investment in 2022?
A: the company fully listens to the opinions and suggestions of the majority of investors on the development of the company, and strictly controls the investment scale of the secondary market on the basis of the original risk control measures. In 2022, within the limit approved by the board of directors, the company will gradually reduce its positions and will not continue to increase its holdings.
3. What are the business highlights of the company’s pharmaceutical division in 2021?
A: in 2021, the pharmaceutical business department adheres to the development concept of “linking specialties and users with services”, with the pharmaceutical operation center as the core and the device operation center and new channel operation center as the two wings. Through sector synergy, we can form distinctive competitive advantages and industry influence. The pharmaceutical operation center has established professional academic IP (value content) projects and competitive IP projects to continuously empower Yunnan Baiyao Group Co.Ltd(000538) series products, classic general medicine series products and Panax notoginseng family products. Through deep market exploration, global marketing and all-round efforts, it has won public praise and market. The device operation center selects two sub areas of chronic disease pain and eye health, focuses on the ecological chain of “specialty, product and service” for positioning and promotion, and outputs functional, intelligent and digital family wearable devices, traditional Chinese medicine diagnosis and treatment equipment and other medical products. The new channel operation center grasps the opportunities of new tracks such as pharmaceutical e-commerce, Internet medicine and short video platform, shapes new scenes, educates new people, and creates a brand unique internet marketing IP and rapid growth model.
April 1, 2022
